Allergan preparing to split after years of turmoil: analyst by Eric Sagonowsky Wednesday, June 19, 2019 Allergan's shares have significantly fallen from their highs in 2015, but now the company is ready to make a big move, one analyst writes.
BMS-Celgene integration questions? Execs aren't answering by Arlene Weintraub Friday, April 26, 2019 Analysts pounded the CEOs of BMS and Celgene for details about their integration plans. But investors seemed dissatisfied with their answers.
'Old guard' generics players yield U.S. scripts lead by Angus Liu Thursday, April 18, 2019 Traditional generics bigwigs Teva, Mylan, Sandoz, Amneal and Endo have lost out to a group of six competitors in terms of U.S. weekly prescriptions.
Already delayed in lung cancer, BMS pulls crucial Opdivo filing by Carly Helfand Thursday, January 24, 2019 Investors panicked in October when Bristol-Myers Squibb said a request for more data from a key lung cancer trial had pushed back an FDA decision.
Pfizer, Merck topped the Dow in 2018 despite biopharma declines by Arlene Weintraub Wednesday, January 2, 2019 Key oncology wins helped drive Pfizer and Merck to the top of the Dow in 2018, but the pharma sector faces plenty of hurdles this year.
Merck hikes prices on Keytruda, Gardasil and more by Eric Sagonowsky Thursday, November 29, 2018 Among small batch of price increases for the pharma giant was a 1.5% increase on superstar cancer drug Keytruda and 6% on HPV shot Gardasil.
Investors hyperfocused on I-O data are still salivating for more by Carly Helfand Thursday, December 21, 2017 If 2016 was the year immuno-oncology first stopped looking invincible, 2017 was the year trial misses became more commonplace.
Opdivo-Yervoy combo hits and misses in kidney cancer trial by Tracy Staton Wednesday, August 16, 2017 If you’re looking for certainty in immuno-oncology, Bristol-Myers’ latest Opdivo-plus-Yervoy data won't help.
Merck's Keytruda delivers surprise fail in head and neck trial by Tracy Staton Tuesday, July 25, 2017 The immunotherapy mystery deepens. Merck’s Keytruda missed its goal in a head and neck cancer trial—one its Bristol-Myers rival Opdivo met last year.
FDA sidelines Keytruda myeloma studies after trial deaths by Carly Helfand Thursday, July 6, 2017 The FDA slapped a clinical hold on two Keytruda trials, dashing Merck's hopes of combining the IO star with one of Celgene's big-selling myeloma meds.